Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer

Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib with docetaxel may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining erlotinib with docetaxel in treating patients who have stage IV or recurrent breast cancer.

Timeline

Start

2002-12

Primary completion

2010-04

Completion

2012-11

Drugs

Indications